# Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

> **NCT01421173** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 78 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Infusion
- **DRUG:** Rituximab
- **DRUG:** G-CSF
- **DRUG:** Palifermin
- **DRUG:** Dexamethasone acetate

## Key facts

- **NCT ID:** NCT01421173
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2015-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421173, "Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01421173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*